Experimental cell therapy for advanced cancers shows early promise but study halted
NCT ID NCT06077903
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a personalized cell therapy called GT101 in 10 adults with advanced solid tumors that had spread or come back. The treatment involved collecting the patient's own immune cells from the tumor, growing them in a lab, and giving them back along with chemotherapy and interleukin-2. The main goal was to check safety, but the study was stopped early.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- What does a healthy mouth mean for people with disabilities?
- Hidden toll of routine ICU procedure revealed: suctioning may spike pain and stress
- New drug duo takes on recurrent brain cancer
- Spinach showdown: does how It's grown affect your blood pressure?
- Video instruction may cut medication errors in kidney transplant patients
- Bone marrow secrets could predict chemo success in leukemia